LAUSR

There is no connection between an RTI employee's compensation and the projects on which they work. Information about projects with other clients is confidential. Comenencia-Ortíz, E: Employment Leadership Position: Roche, Genentech; Stock Ownership: Roche, Genentech; Other Remuneration: Employment by a for-profit health care company that funded any part of this research: Genentech. Masaquel, A: Employment Leadership Position: Genentech, Inc.; Stock Ownership: Roche. Ravelo, A: Employment Leadership Position: Genentech; Stock Ownership: Genentech. 516 REAL-WORLD ASSESSMENT OF PRACTICE EFFICIENCY WITH THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB M.J. Matasar | A. Qiu | S. Shapouri | E.N. Drill | J. Schade | A. Ravelo | A. Ni | T.M. To | K.L. Dawson Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; US Medical Affairs, Genentech, Inc., South San Francisco, CA, United States; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States Introduction: Rituximab (R), available as an intravenous (IV; R-IV) infusion or subcutaneous (SC; R-SC) injection, is used in the treatment of follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukaemia (CLL). This study evaluated real-world practice efficiency changes associated with the adoption of R-SC by studying differences in chair time by route of administration. Methods: We conducted a retrospective analysis of practice care delivery measures before and after adoption of R-SC at Memorial Sloan Kettering Cancer Center (MSKCC). Data for patients (pts) with FL, DLBCL or CLL receiving R-based therapy from September 2016 to September 2018 were extracted from the electronic medical record. A linear mixed effect multivariate model with random intercept was used to analyse the association between treatment type (R-IV vs R-SC) and chair time (defined as the difference in pt room-in and room-out times) in the year prior to and following R-SC adoption at MSKCC. Model covariates included treatment time and location, therapy type (monotherapy vs combination) and pt demographics. Given the prolonged infusion time, pts' first dose of R-IV was excluded from the analysis. Results: Data were collected during 6744 visits (3018 visits prior to R-SC adoption and 3726 after) for 1503 pts receiving R. Pts receiving R-IV combination therapy had a mean chair time of 203 minutes (min); overall, R-SC injection reduced chair time by a mean of 92 min (p<0.001 vs R-IV). Monotherapy, regardless of route, reduced chair time by a mean of 30 min (p<0.001) compared with combination therapy, and mean chair time was further reduced by 39 min (p<0.001) for R-SC pts receiving monotherapy. Reductions in chair time increased over time following initial adoption of R-SC (p=0.042), and were greater at the lymphoma-specific site than multispecialty oncology infusion centres (p<0.001). Conclusions: Adoption of R-SC results in substantial time savings for both the pt and health system as measured by reduced chair time and improved pt throughput. Given increasing constraints on infusion chair space, increased utilisation of R-SC may improve practice efficiency and pt access to care. Acknowledgment: Third-party editorial assistance, under the direction of Annie Qiu and Sheila Shapouri, was provided by Scott Malkin of Gardiner-Caldwell Communications, and was funded by F. HoffmannLa Roche Ltd. © 2019 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2019 ASCO Annual Meeting. All rights reserved.